Who
Craig A. Collard
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Heron Therapeutics; Director, TerrAscend; Director, Opiant Pharmaceuticals; Director, Sierra Oncology; Chief Executive Officer, Cornerstone Therapeutics.
In numbers
- Trades disclosed
- 142
- Buys
- 11
- Sells
- 3
- Bought
- $1.1M
- Sold
- $18.2M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 31 Oct 2008
- Last trade
- 19 Oct 2026
- Last filed
- 21 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Oct 2026filed 21 Oct 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —13,797 | filing |
| 19 Oct 2026filed 21 Oct 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,2103,360 at $0.36 | filing |
| 19 Oct 2026filed 21 Oct 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,797 at $0.00 | filing |
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —34,789 | filing |
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —34,789 at $0.00 | filing |
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —34,789 at $0.00 | filing |
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —34,789 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —50,021 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,021 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,021 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —50,021 | filing |
| 19 Jul 2026filed 20 Jul 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —13,797 | filing |
| 19 Jul 2026filed 20 Jul 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,797 at $0.00 | filing |
| 19 Jul 2026filed 20 Jul 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,797 at $0.00 | filing |
| 19 Jul 2026filed 20 Jul 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —13,797 | filing |
| 24 Jun 2026filed 25 Jun 2026 | TerrAscendoption or derivative | SEC FORM 4 Code D | —150,000 | filing |
| 24 Jun 2026filed 25 Jun 2026 | TerrAscendoption or derivative | SEC FORM 4 Code A | —150,000 | filing |
| 30 Apr 2026filed 4 May 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —34,789 | filing |
| 30 Apr 2026filed 4 May 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —50,021 | filing |
| 30 Apr 2026filed 4 May 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —34,789 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.